The active ingredient toremifene is a representative of triphenylethylene and has the property of contacting with estrogen receptors and producing a similar or anti-estrogenic effect. At the same time, a slight decrease in the serum cholesterol level is observed.
Fareston forms a bond with estrogen receptors and blocks the indirect activation of DNA production and the process of cell replication. Studies have confirmed the estrogen-independent anti-cancer effect of the drug.
It is assumed that at the moment, not all the links of the anti-cancer effect of Fareston have been studied. Probably, treatment with a drug provokes changes in oncogenic expression, affects the kinetic properties of the cell cycle, etc.